NFE2L2 and Alzheimer disease: Finally, Resveratrol—currently under investigation in AD clinical trials—not only activates NRF2, but also promotes non-amyloidogenic APP processing by enhancing α-secretase and suppressing β-secretase activity, further supporting its neuroprotective role [73].